Jon Chancellor, MD
Family Medicine · Kerrville, TXNPI 1598708794
Payments from drug & device makers
Across 337 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$1K
- Pacira Pharmaceuticals Incorporated$947
- AbbVie$657
- Daiichi Sankyo Inc.$586
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$279
- plus $2K from 32 others
What the payments were for
- Consulting fees$1,16516%
- Travel & lodging$83211%
- Food & beverage$5,33473%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 93 | $1,429 |
| AstraZeneca | 1 | $1,165 |
| Pacira Pharmaceuticals Incorporated | 7 | $947 |
| AbbVie(2 entities) | 43 | $657 |
| Daiichi Sankyo Inc. | 31 | $586 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $279 |
| Lilly USA, LLC | 17 | $273 |
| Pfizer | 13 | $211 |
| Pacira Therapeutics, Inc. | 21 | $185 |
| Kowa Pharmaceuticals America, Inc. | 9 | $166 |
| Exact Sciences | 8 | $155 |
| Eisai Inc. | 9 | $150 |
| Almatica Pharma LLC | 11 | $139 |
| Boehringer Ingelheim | 6 | $126 |
| Novo Nordisk | 5 | $90 |
| GSK | 5 | $84 |
| Vertex | 3 | $61 |
| Amarin Pharma, Inc. | 3 | $60 |
| Johnson & Johnson(2 entities) | 4 | $59 |
| Novartis | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Orthogenrx Inc. | 2 | $39 |
| Fidia Pharma USA Inc. | 2 | $36 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Bayer | 2 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Merck | 2 | $25 |
| Lundbeck LLC | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Globus Medical | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Abbott | 1 | $14 |
| Bioventus LLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,336 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 69 | $93,202 |
| OzempicSemaglutide | 81 | $78,220 |
| EliquisApixaban | 55 | $46,143 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $45,119 |
| MounjaroTirzepatide | 26 | $30,316 |
| LinzessLinaclotide | 28 | $25,656 |
| MyrbetriqMirabegron | 29 | $24,610 |
| JanuviaSitagliptin Phosphate | 19 | $21,481 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $19,237 |
| TrulicityDulaglutide | 11 | $16,353 |
| JentaduetoLinagliptin/Metformin Hcl | 12 | $5,686 |
| Levothyroxine Sodium | 426 | $5,137 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $5,137 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 169 | $4,875 |
| SynthroidLevothyroxine Sodium | 62 | $4,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Jentadueto | $126 | $98,88881 claims |
| Novo NordiskOzempic | $90 | $78,22081 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $84 | $64,35577 claims |
| Lilly USA, LLCMounjaro, Trulicity | $273 | $46,66937 claims |
| PfizerEliquis | $211 | $46,14355 claims |
| AbbVieLinzess, Synthroid | $657 | $29,75990 claims |
| MerckJanuvia | $25 | $21,48119 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $35 | $5,137426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Kerrville
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.